BMY Bristol Myers Squibb
Health Care · Pharmaceuticals · close $59.75 (2026-10-16) · latest quarter in EDGAR: 2026-06-30
Bristol Myers Squibb (BMY) has a ThetaGrade House Rating of 62/100 (grade C), ranking #49 of 150 in Health Care. Its strongest pillars are cash flow (93) and valuation (82); its weakest is balance sheet (41). TTM revenue growth is 3.1% and operating margin 24.2%.
Data as of .
Analyst sentiment
weight 7.5% · 50| Consensus score (1–5) (3.8%) | derived | 9 |
| 90-day net rating shift (3.8%) | derived | 70 |
Growth
weight 30.83% · 57| Revenue growth YoY (TTM) (12.3%) | 3.1% | 17 |
| EPS growth YoY (TTM) (12.3%) | 82.7% | 88 |
| Revenue acceleration (6.2%) | 3.2% | 75 |
Profitability
weight 18.5% · 61| Operating margin (9.9%) | 24.2% | 80 |
| 4Q gross-margin change (8.6%) | -0.1% | 40 |
Balance sheet
weight 18.5% · 41| Net debt / EBITDA (9.9%) | 2.14× | 41 |
| Current ratio (4.9%) | 1.53 | 28 |
| Interest coverage (3.7%) | 6.30× | 60 |
Cash flow
weight 12.33% · 93| FCF margin (6.2%) | 26.7% | 88 |
| FCF yield (6.2%) | 10.5% | 98 |
Valuation
weight 12.33% · 82| P/E (inverted) (6.2%) | 13.13× | 94 |
| EV/Sales (inverted) (6.2%) | 3.18× | 69 |
Technicals (EOD)
| RSI(14) | 44.3 |
| EMA 9 / 21 | 59.52 / 60.65 |
| 200-day SMA | 59.64 |
| Volume vs 20d avg | 0.93× |
| 20-day return | -4.9% |
Exit-rule monitor
No exit or watch rules triggered.
Data source per metric (SEC XBRL tag or derivation): Revenue: Revenues · Gross profit: Revenue − CostOfGoodsAndServicesSold · Operating income: Revenue − CostsAndExpenses · Interest expense: InterestExpenseNonoperating · D&A: DepreciationDepletionAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).
Get rating changes like BMY's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is BMY's House Rating?
- BMY scores 62 out of 100 (grade C) as of 2026-10-16, ranking #49 of 150 Health Care stocks we cover.
- What do analysts say about BMY?
- ThetaGrade's analyst-sentiment pillar for BMY scores 50/100 against its sector peers, which we read as mixed. This is our own derived score; we do not republish individual analyst ratings, counts or targets.
- When does BMY report earnings next?
- BMY's next earnings report is estimated for about 2026-10-29 (window 2026-10-22 to 2026-11-05), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.
- Is BMY a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology